Breaking News, Collaborations & Alliances

Monte Rosa, Novartis Partner to Advance Molecular Glue Degraders

Aims to accelerate MRT-6160 clinical development and explore therapeutic opportunities across multiple indications.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Monte Rosa Therapeutics, Inc., a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, entered an exclusive global development and commercialization license agreement with Novartis to advance VAV1 MGDs, including MRT-6160.    MRT-6160 is currently in Phase 1 development in healthy volunteers for immune-mediated conditions. Under the agreement, Novartis will obtain exclusive worldwide rights to develop, manufacture and commercialize MRT-6160 and other VAV1 MGDs a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters